Nano Covax developed by the NanogenPharmaceutical Biotechnology Company is Vietnam’s first candidate vaccine to reachthe human trial stage.
According to Associate Prof. Dr. Chu Van Men, Director of the Military Medical University’sCentre for Clinical Trials and Bioequivalence, after receiving the first shots,volunteers exhibited symptoms such as pain at the injection point, a light fever, muscle aches, joint pain, and fatigue, but did notrequire medical intervention.
The health of the 560 volunteers remains stable, he said, adding that NanoCovax is safe and the volunteers are ready for their second shots.
The second trial is being organised simultaneously at the Military Medical Universityand the Pasteur Institute in Ho Chi Minh City, with volunteers including thosewith mild background ailments such as hypertension, diabetes, and cardiovascularissues.
As planned, the MilitaryMedical University will submit the preliminary test results to the Ministry of Healthand the National Council for Ethics in Biomedical Research in May forreview and evaluation, before conducting the third phase of trials.
Previously, at ameeting of standing members of the National Steering Committee for COVID-19 Preventionand Control, a representative from the Ministry of Health said that the third phaseof trials will take place from May to September, with the vaccine then registeredfor circulation in September, three months earlier than scheduled.
Vietnam expects to have its locally-produced vaccine available by the end of thethird quarter./.